Mark Ericson

Title: Mark Ericson: Innovator in Cyclic Peptides and Melanocortin Ligands

Introduction

Mark Ericson is a notable inventor based in Minneapolis, MN (US). He has made significant contributions to the field of biochemistry, particularly in the development of cyclic peptides and melanocortin ligands. With a total of 2 patents to his name, Ericson's work has the potential to impact various applications in medicine and biotechnology.

Latest Patents

Ericson's latest patents include innovative compounds and methods that showcase his expertise. One of his patents focuses on cyclic peptides and methods of use thereof. This invention provides a cyclic compound with specific residues, including L-proline and various amino acids, along with compositions and methods for utilizing these compounds. Another patent involves chimeric melanocortin ligands, which presents compounds with a general formula and their respective salts. This invention also includes compositions containing these compounds and methods for their application.

Career Highlights

Mark Ericson is affiliated with the University of Minnesota, where he continues to advance his research and innovation in the field. His work has garnered attention for its potential applications in therapeutic settings, particularly in the development of new treatments.

Collaborations

Ericson collaborates with Carrie Haskell-Luevano, a fellow researcher, to further explore the applications of their inventions. Their combined expertise enhances the potential impact of their work in the scientific community.

Conclusion

Mark Ericson's contributions to the field of cyclic peptides and melanocortin ligands demonstrate his commitment to innovation and research. His patents reflect a dedication to advancing biochemistry and its applications in medicine.